Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference

Rhea-AI Summary

Austin, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) - Lumos Pharma (NASDAQ: LUMO), a biopharmaceutical company, announced its participation in the upcoming Cantor Neurology & Psychiatry Conference on October 6-7. Management will engage in a panel discussion titled 'Broken circuits. Modulating the neuroendocrine systems to reestablish equipoise' on October 7 at 10:10 AM PT. Additionally, one-on-one meetings will be available on both conference days. Lumos Pharma is advancing its oral therapeutic candidate LUM-201 for Pediatric Growth Hormone Deficiency through Phase 2 clinical trials.

AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October.

	Event:	Cantor Neurology & Psychiatry Conference – October 6th - 7th
	Panel:	“Broken circuits. Modulating the neuroendocrine systems to reestablish equipoise.” Friday, October 7th at 10:10-11:10 AM PT (1:10-2:10 PM ET)
	1x1 Meetings:	Management will be available for one-on-one meetings October 6th & 7th

The panel presentation will be available only to conference participants and will not be webcast. To schedule a virtual or in-person meeting with Lumos Pharma management during the conference, please contact your Cantor sales representative.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

What is Lumos Pharma's participation in the Cantor Neurology & Psychiatry Conference?

Lumos Pharma will participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022, engaging in a panel discussion and hosting one-on-one meetings.

What is the panel discussion topic at the conference?

The panel discussion is titled 'Broken circuits. Modulating the neuroendocrine systems to reestablish equipoise' and will take place on October 7 from 10:10 AM PT.

What is LUM-201 and its significance?

LUM-201 is Lumos Pharma's lead oral therapeutic candidate for Pediatric Growth Hormone Deficiency, currently in Phase 2 clinical trials, offering an alternative to injections.

When will one-on-one meetings with Lumos Pharma management be available?

One-on-one meetings with Lumos Pharma management will be available on October 6 and 7 during the conference.

Has LUM-201 received any designations?

Yes, LUM-201 has received Orphan Drug Designation in both the US and EU for its potential in treating Pediatric Growth Hormone Deficiency.